DASATINIB VIATRIS dasatinib 100 mg film coated tablet blister pack

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

dasatinib, Quantity: 100 mg

Verfügbar ab:

Helix Pharmaceuticals Pty Ltd

Darreichungsform:

Tablet, film coated

Zusammensetzung:

Excipient Ingredients: croscarmellose sodium; colloidal anhydrous silica; lactose monohydrate; hyprolose; ethylcellulose; hypromellose; magnesium stearate; triethyl citrate; titanium dioxide; microcrystalline cellulose

Verabreichungsweg:

Oral

Einheiten im Paket:

30

Verschreibungstyp:

(S4) Prescription Only Medicine

Anwendungsgebiete:

DASATINIB VIATRIS is indicated for the treatment of adults aged 18 years or over with: ? Newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia in the chronic phase ? Chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib ? Philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy

Produktbesonderheiten:

Visual Identification: White to off-white, oval, bevelled-edged, biconvex coated tablet. Engraved "APO" on one side "DAS100" on the other side.; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Berechtigungsstatus:

Registered

Berechtigungsdatum:

2018-07-31